Type II Diabetes in Mild Cognitive Impairment and Alzheimer’s Disease: Results from a Prospective Population-Based Study in Germany

Pablo Toro, Peter Schönknecht and Johannes Schröder*
Section for Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany

Abstract. Diabetes mellitus type 2 (T2DM) is considered to be an important risk factor for mild cognitive impairment (MCI) and subsequent Alzheimer’s disease (AD). The majority of studies relating T2DM to MCI and AD were performed in North America. We investigated the potential impact of T2DM on the development of MCI and AD in the Interdisciplinary Longitudinal Study on Adult Development and Aging which involves a representative birth cohort of subjects born between 1930 and 1932 in Germany. Subjects received a thorough psycho-geriatric examination and neuropsychological testing; particular care was taken to exclude subjects with severe medical or neurological conditions sufficient to explain the cognitive deficits, or other major psychiatric disorders. When compared to healthy subjects (n = 159), patients with MCI (n = 108) or AD (n = 26) showed a tendency towards increased prevalence rates for T2DM (16% vs. 23%; χ² = 1.7, p = 0.18). In both patients with MCI and controls, T2DM was associated with psychomotor slowing but not deficits in other cognitive domains typically involved in MCI. Our findings indicate that T2DM is involved in MCI and may aggravate the clinical picture as a concomitant factor.

Keywords: Aging-associated cognitive decline, Alzheimer’s disease, diabetes mellitus, Interdisciplinary Longitudinal Study on Adult Development and Aging, mild cognitive impairment

INTRODUCTION

Diabetes mellitus type 2 (T2DM) is not solely an important health problem in the United States and throughout the western world, but is considered to be an important risk factor for mild cognitive impairment (MCI) and subsequent Alzheimer’s disease (AD). In Germany, the prevalence of T2DM is rising: while in a 1998 survey, the prevalence over all ages was at 5.9%, it reached 7.9% in 2004 [1]. For people over the age of 60, T2DM prevalence rates are estimated to range between 18 and 28%, reflecting the importance of this disease in the young old. Although the relationship between T2DM, hyperinsulinemia, and dementia has been addressed in a number of studies (for a review see [2]), most of them used samples comprising a wide range of age (i.e., 60–75 years) and showed divergent findings: some relating T2DM to AD and MCI [3–5] and others finding no association or only an association with vascular dementia (VaD) [6–8].

On basis of these epidemiological findings, a number of factors – hyperinsulinemia, advanced glycation end products, adipokines and cytokines, and vascular risk factors – were hypothesized linking T2DM and AD [2,9]. The former three refer to pathophysiological changes supposed to directly interfere with the metabolism of amyloid-β. Hence, one may expect that these changes should aggravate the clinical picture of MCI or AD. The potential impact of vascu-
far risk factors and the respective changes in amyloid-
β metabolism is not yet fully understood. However,
these changes may pose rather global effects on cere-
bral functioning which not only apply for MCI or AD
but can affect T2DM patients in general. One way to
test this hypothesis in a clinical study is to compare
patterns of neuropsychological functioning in patients
with MCI or AD and healthy controls with and with-
out T2DM. If T2DM had specific effects on MCI and
AD, it should aggravate the typical neuropsychological
deficits. Alternatively, global effects of T2DM should
lead to rather unspecific neuropsychological changes
which strike all patients with T2DM irrespective of a
potential cognitive diagnosis.

Symptomatic cognitive deficits due to severe med-
ical or neurological diseases, or mild cognitive disor-
der (MCD) according to the International Statistical
Classification of Diseases and Related Health Problems
(ICD-10) criteria, have to be considered as an important
potentially confounding variable. Patients suffering from
typical medical complications of diabetes secondary to
an advanced micro- and macro-angiopathy as prolifera-
tive retinopathy, peripheral neuropathy, and peripheral
vascular disease fall into this category.

In the present study, we investigated the potential
impact of T2DM on the development of MCI and AD
in the Interdisciplinary Longitudinal Study on Adult
Development and Aging (ILSE) which involves a rep-
resentative birth cohort of subjects born between 1930
and 1932 in Germany. The aim of our study was: 1) to
confirm and enhance the epidemiological findings on
the association between T2DM, MCI and AD; and 2)
to investigate the question whether T2DM is directly
involved in the pathogenesis of the disease or acts as a
concomitant factor.

METHODS

Subjects

The ILSE is a prospective study on adult develop-
ment in Germany based on two birth cohorts born in
1930–1932 and 1950–1952 [10]. Participants were
randomly identified and recruited according to com-
community registers which are compulsory for any citizen
aged 16 and above in Germany; this recruitment proce-
dure yielded an almost representative sample for the
respective communities. Subjects have been followed up
since 1993/94 for at least 13 years. The present study is
based on the results of 381 participants from the 1930–
1932 birth cohort who completed the 3rd examination
wave at an average age of 75 years.

The participants were carefully screened for physi-
cal and mental health by extensive interviews, physical
examination and laboratory tests including cholesterol,
triglycerides and glycosylated hemoglobin (HbA1c)
performed by a physician. In addition, potential psy-
chiatric disorders were assessed clinically and by us-
ing the German version of the Structured Clinical In-
terview for the Diagnostic and Statistical Manual of
Mental Disorders (DSM-III-R) [11]. The study was
approved by the ethics committee of the University of
Heidelberg. After complete description of the study to
the subjects, written informed consent was obtained.

Severity of cognitive deficits was assessed by the
Mini-Mental State Examination (MMSE) [12]. In ad-
dition, the subtests logical memory I and II of the Wech-
sler Memory Scale (WMS), German version [13] and
the Trail Making Test (TMT) [14] were applied to ad-
dress memory and learning, and attention and cogni-
tive flexibility, respectively (a detailed description of
the neuropsychological test battery used is given else-
where [15]).

Diagnostic categories

MCI was diagnosed according to the aging-associated
cognitive decline (AADC) criteria as described else-
where [16]. MCD was diagnosed using ICD-10 cri-
teria, respectively (for details see [15]). For the di-
agnosis of AD and VaD, the NINCDS-ADRDA and
the NINDS-AIREN criteria were applied [17,18]. All
diagnoses were the result of a consensus conference
of two specialists in psychiatry under supervision of
a specialist in Old Age Psychiatry. The diagnosis of
diabetes was established by history taking, clinical ex-
amination and laboratory data. Moreover, the patient’s
family physician was contacted if information was in-
complete.

Statistics

SAS software (version 9.01; SAS Institute, Cary,
NC, USA) was used for all statistical analysis; p-values
less than 0.05 were considered significant. Analyses of
variance with post hoc Duncan’s tests were calculated
in order to compare the demographic and clinical data
between the diagnostic groups. Gender and diabetes
distributions were analyzed by the $\chi^2$-test.
†1 not reach significance level ($\chi^2 = 0.18$). As expected, mean MMSE scores differed significantly among all three groups ($F = 100.57, p < 0.0001$) with the MCI group ranking in between AD patients and controls. According to WMS I ($F = 123.34, p < 0.0001$), WMS II ($F = 183.65, p < 0.0001$), TMT A ($F = 30.32, p < 0.0001$), and TMT B ($F = 49.22, p < 0.0001$) were best accomplished by the controls and least by the AD patients.

In Table 2, the MCI and the control group were classified according to the presence or absence of T2DM. Multivariate analyses of variance yielded significant main effects for “cognition” in all variables under investigation except HbA1c (1.61 < $F$ < 147.71), whereas the main effect “T2DM” were significant for HbA1c and performance in the TMT A and TMT B (0.05 < $F$ < 67.41) only. The interaction "cognition * di-
diabetes” did not reach significance level for any of the variables included (0.01<\text{F}<1.09).

DISCUSSION

The present study yielded two major findings: 1) support for a somewhat increased prevalence rate of T2DM in MCI and AD although this difference did not reach significance level; and 2) an indication that T2DM may lead as a concomitant disorder to psychomotor slowing and impaired cognitive flexibility in patients with MCI as well as controls.

As to be expected, neuropsychological performance differed between the diagnostic groups with AD patients followed by those with MCI showing significant deficits when compared to the healthy controls. The former groups were also characterized by a lower educational level as a putative surrogate of cognitive reserve [19].

The slight increase of prevalence rates for T2DM in both patients with MCI and AD corresponds with the studies published by Luchsinger 2007 and Ott 1999 which reported a significant increase on the basis of large population samples recruited in northern Manhattan and Rotterdam. Whereas similar prevalence rates between 20 and 30% for T2DM were reported for patients with MCI and AD, rates obtained among the controls varied considerably from 10.5% [5] to 17.0% in the present study and 21.6% [4]. The overall T2DM prevalence rate of 20.2% obtained in the present study is well in the range reported for this age group in the German population. From these data, one may conclude that the negative results of our study are likely to be accounted for by the sample size. However, an Italian study [8] also reported slightly but not significantly increased prevalence rates for T2DM in a sample of 2963 participants recruited from the general population. Along with this, the Canadian study of health and aging described a significant association for VaD but not AD [6], whereas Luchsinger could confirm an increased T2DM prevalence neither for AD nor for “non dementia cognitive impairment without stroke” after controlling for apolipoprotein ε4 status [7]. Obviously, these discrepancies may refer to methodological issues, such as the use of different diagnostic categories or the consideration of co-morbidity with psychiatric diseases. The majority of studies used Petersen’s MCI criteria for clinical diagnosis; however, the validity of the AACCd criteria applied in the present investigation is underlined by the finding of similar T2DM prevalence rates in patients with MCI and AD. Co-morbidity with other major psychiatric disorders, in particular major depression, was not addressed although the former can be associated with T2DM and related conditions. Therefore, particular care was taken to exclude subjects with a history of major psychiatric diseases such as major depression or substance abuse in the present study.

In a second step, potential effects of T2DM as a concomitant disorder were examined by analyzing its potential impact on the neuropsychological performance. A significant diabetes effect was restricted to the attention-concentration task TMT A and the cognitive flexibility test TMT B both of which share a psychomotor component. In contrast, those neuropsychological domains typically affected in early AD or MCI, i.e., memory or learning were not affected by diabetes. The same applied for global cognitive performance as measured by the MMSE. This double dissociation suggests that T2DM may act as a concomitant disorder affecting psychomotor speed rather than other cognitive domains typically involved in AD.

Since the treatment of diabetes is covered by the social system in Germany, and all ILSE participants with T2DM were assisted (medically and/or by a nutritionist) in achieving good glucose control, the T2DM effect on cognition is probably well balanced and minimized in the present sample as suggested by the low HbA1c blood levels observed in the T2DM group. Moreover, patients with MCD, i.e. those suffering from somatic diseases sufficient to impair cognition including patients with the typical clinical complications of T2DM such as proliferative retinopathy, peripheral neuropathy, and peripheral vascular disease, were excluded. A similar pattern of neuropsychological deficits with psychomotor slowing but sparing of mnemonic abilities was consistently described by Ryan and colleagues in otherwise healthy patients with T2DM when compared to controls [20]. They suggested a “central neuropathy” which would be probably induced by chronic hyperglycemia; while psychomotor slowing was best predicted by the presence of clinically significant biomedical complications its pathogenesis and why other cognitive skills are relatively unaffected remains poorly understood.

In conclusion, our findings conform with an effect of T2DM on MCI and AD as emphasized in recent studies. The question if T2DM is directly involved in the pathogenesis of AD and MCI as its putative preclinical state or complicates the clinical condition of patients as a concomitant disorder needs to be investigated further.
ACKNOWLEDGMENTS

The ILSE was supported by the Forschungsprogramm des Landes Baden-Württemberg and the Federal Ministry for Family, Senior Citizens, Women, and Youth; P. Toro and J. Schröder received additional support by the Marsilius Kolleg, center of advanced studies, University of Heidelberg. The authors are grateful to Dr. Aoife Hunt for proofreading the manuscript.

Peter Schönknecht is a consultant to Pfizer and has received speaker fees from Astra-Zeneca, Pfizer, Janssen, Lilly and Novartis.

References


